🚀 VC round data is live in beta, check it out!
Inhalation Sciences SWE Valuation Multiples
Discover revenue and EBITDA valuation multiples for Inhalation Sciences SWE and similar public comparables like Work Medical Technology Group, Perpetua Medical, BBS-Bioactive Bone, Luxbright and more.
Inhalation Sciences SWE Overview
About Inhalation Sciences SWE
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.
Founded
2004
HQ
Employees
9
Website
Sectors
Financials (FY)
EV
$1M
Inhalation Sciences SWE Financials
Inhalation Sciences SWE reported last fiscal year revenue of $332K and negative EBITDA of ($1M).
In the same fiscal year, Inhalation Sciences SWE generated $282K in gross profit, ($1M) in EBITDA losses, and had net loss of ($1M).
Inhalation Sciences SWE P&L
In the most recent fiscal year, Inhalation Sciences SWE reported revenue of $332K and EBITDA of ($1M).
Inhalation Sciences SWE expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $332K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $282K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 85% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($1M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (319%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (334%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (334%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Inhalation Sciences SWE Stock Performance
Inhalation Sciences SWE has current market cap of $2M, and enterprise value of $1M.
Market Cap Evolution
Inhalation Sciences SWE's stock price is $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1M | $2M | 0.3% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInhalation Sciences SWE Valuation Multiples
Inhalation Sciences SWE trades at 3.6x EV/Revenue multiple, and (1.1x) EV/EBITDA.
Inhalation Sciences SWE Financial Valuation Multiples
As of April 20, 2026, Inhalation Sciences SWE has market cap of $2M and EV of $1M.
Equity research analysts estimate Inhalation Sciences SWE's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inhalation Sciences SWE has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV (current) | $1M | XXX | $1M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.2x | XXX | XXX | XXX |
| P/E | — | XXX | (1.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Inhalation Sciences SWE Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Inhalation Sciences SWE Margins & Growth Rates
Inhalation Sciences SWE's revenue in the last fiscal year declined by (72%).
Inhalation Sciences SWE's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Inhalation Sciences SWE Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (72%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (319%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 146% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 139% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 144% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 137% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 419% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Inhalation Sciences SWE Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Inhalation Sciences SWE | XXX | XXX | XXX | XXX | XXX | XXX |
| Work Medical Technology Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Perpetua Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| BBS-Bioactive Bone | XXX | XXX | XXX | XXX | XXX | XXX |
| Luxbright | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inhalation Sciences SWE M&A Activity
Inhalation Sciences SWE acquired XXX companies to date.
Last acquisition by Inhalation Sciences SWE was on XXXXXXXX, XXXXX. Inhalation Sciences SWE acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Inhalation Sciences SWE
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInhalation Sciences SWE Investment Activity
Inhalation Sciences SWE invested in XXX companies to date.
Inhalation Sciences SWE made its latest investment on XXXXXXXX, XXXXX. Inhalation Sciences SWE invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Inhalation Sciences SWE
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Inhalation Sciences SWE
| When was Inhalation Sciences SWE founded? | Inhalation Sciences SWE was founded in 2004. |
| Where is Inhalation Sciences SWE headquartered? | Inhalation Sciences SWE is headquartered in Sweden. |
| How many employees does Inhalation Sciences SWE have? | As of today, Inhalation Sciences SWE has over 9 employees. |
| Is Inhalation Sciences SWE publicly listed? | Yes, Inhalation Sciences SWE is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Inhalation Sciences SWE? | Inhalation Sciences SWE trades under ISAB ticker. |
| When did Inhalation Sciences SWE go public? | Inhalation Sciences SWE went public in 2017. |
| Who are competitors of Inhalation Sciences SWE? | Inhalation Sciences SWE main competitors are Work Medical Technology Group, Perpetua Medical, BBS-Bioactive Bone, Luxbright. |
| What is the current market cap of Inhalation Sciences SWE? | Inhalation Sciences SWE's current market cap is $2M. |
| What is the current revenue of Inhalation Sciences SWE? | Inhalation Sciences SWE's last fiscal year revenue is $332K. |
| What is the current EV/Revenue multiple of Inhalation Sciences SWE? | Current revenue multiple of Inhalation Sciences SWE is 3.6x. |
| Is Inhalation Sciences SWE profitable? | No, Inhalation Sciences SWE is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.